22.16
0.24 (1.09%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Nurix Therapeutics, Inc. | Bullish | Bearish |
Stockmoo Score
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Truist Securities, 62.46%) | Buy |
| Median | 30.00 (35.38%) | |
| Low | 26.00 (HC Wainwright & Co., 17.33%) | Buy |
| Average | 30.43 (37.32%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 22.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 04 Sep 2024 | 30.00 (35.38%) | Buy | 24.69 |
| 14 Aug 2024 | 27.00 (21.84%) | Buy | 21.92 | |
| Truist Securities | 31 Jul 2024 | 36.00 (62.45%) | Buy | 21.88 |
| Barclays | 15 Jul 2024 | 31.00 (39.89%) | Buy | 22.68 |
| JP Morgan | 15 Jul 2024 | 34.00 (53.43%) | Buy | 22.68 |
| 17 Jun 2024 | 31.00 (39.89%) | Buy | 15.29 | |
| Needham | 12 Jul 2024 | 29.00 (30.87%) | Buy | 23.82 |
| 17 Jun 2024 | 31.00 (39.89%) | Buy | 15.29 | |
| RBC Capital | 12 Jul 2024 | 27.00 (21.84%) | Buy | 23.82 |
| 27 Jun 2024 | 26.00 (17.33%) | Buy | 20.74 | |
| HC Wainwright & Co. | 18 Jun 2024 | 26.00 (17.33%) | Buy | 18.44 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 24.86 | -9,050 | -224,983 |
| Aggregate Net Quantity | -9,050 | |||
| Aggregate Net Value ($) | -224,983 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 24.86 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Officer | 03 Sep 2024 | Automatic sell (-) | 9,050 | 24.86 | 224,983 |
| RING CHRISTINE | Officer | 03 Sep 2024 | Option execute | 9,050 | - | - |
| Date | Type | Details |
|---|---|---|
| 06 Sep 2024 | Announcement | Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit |
| 29 Aug 2024 | Announcement | Nurix Therapeutics to Participate in Upcoming Investor Conferences |
| 11 Jul 2024 | Announcement | Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update |
| 08 Jul 2024 | Announcement | Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day |
| 16 Jun 2024 | Announcement | Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |